vs
Side-by-side financial comparison of Douglas Elliman Inc. (DOUG) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
Douglas Elliman Inc. is the larger business by last-quarter revenue ($245.4M vs $158.6M, roughly 1.5× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs 27.9%, a 43.3% gap on every dollar of revenue. On growth, Stoke Therapeutics, Inc. posted the faster year-over-year revenue change (3661.1% vs 0.9%). Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $-14.7M).
Douglas Elliman Inc. is a leading U.S.-based residential real estate brokerage firm. It offers luxury property sales, rentals, property management, and advisory solutions, serving high-net-worth clients across key metro markets including New York, California, Florida, and Texas.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
DOUG vs STOK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $245.4M | $158.6M |
| Net Profit | $68.6M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | 27.3% | 70.2% |
| Net Margin | 27.9% | 71.2% |
| Revenue YoY | 0.9% | 3661.1% |
| Net Profit YoY | 1243.4% | 528.0% |
| EPS (diluted) | $0.80 | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $245.4M | — | ||
| Q3 25 | $262.8M | — | ||
| Q2 25 | $271.4M | — | ||
| Q1 25 | $253.4M | $158.6M | ||
| Q4 24 | $243.3M | $22.6M | ||
| Q3 24 | $266.3M | — | ||
| Q2 24 | $285.8M | — | ||
| Q1 24 | $200.2M | — |
| Q4 25 | $68.6M | — | ||
| Q3 25 | $-24.7M | — | ||
| Q2 25 | $-22.7M | — | ||
| Q1 25 | $-6.0M | $112.9M | ||
| Q4 24 | $-6.0M | $-10.5M | ||
| Q3 24 | $-27.2M | — | ||
| Q2 24 | $-1.7M | — | ||
| Q1 24 | $-41.5M | — |
| Q4 25 | 27.3% | — | ||
| Q3 25 | -4.1% | — | ||
| Q2 25 | -2.0% | — | ||
| Q1 25 | -2.1% | 70.2% | ||
| Q4 24 | -6.7% | -60.4% | ||
| Q3 24 | -2.8% | — | ||
| Q2 24 | -1.3% | — | ||
| Q1 24 | -20.7% | — |
| Q4 25 | 27.9% | — | ||
| Q3 25 | -9.4% | — | ||
| Q2 25 | -8.4% | — | ||
| Q1 25 | -2.4% | 71.2% | ||
| Q4 24 | -2.5% | -46.4% | ||
| Q3 24 | -10.2% | — | ||
| Q2 24 | -0.6% | — | ||
| Q1 24 | -20.7% | — |
| Q4 25 | $0.80 | — | ||
| Q3 25 | $-0.29 | — | ||
| Q2 25 | $-0.27 | — | ||
| Q1 25 | $-0.07 | $1.90 | ||
| Q4 24 | $-0.06 | $-0.15 | ||
| Q3 24 | $-0.33 | — | ||
| Q2 24 | $-0.02 | — | ||
| Q1 24 | $-0.50 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $115.5M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $183.9M | $350.1M |
| Total Assets | $444.4M | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $115.5M | — | ||
| Q3 25 | $143.0M | — | ||
| Q2 25 | $136.3M | — | ||
| Q1 25 | $136.8M | $274.8M | ||
| Q4 24 | $145.5M | $128.0M | ||
| Q3 24 | $151.4M | — | ||
| Q2 24 | $92.9M | — | ||
| Q1 24 | $91.5M | — |
| Q4 25 | $183.9M | — | ||
| Q3 25 | $115.1M | — | ||
| Q2 25 | $137.6M | — | ||
| Q1 25 | $158.2M | $350.1M | ||
| Q4 24 | $162.2M | $229.0M | ||
| Q3 24 | $173.6M | — | ||
| Q2 24 | $196.9M | — | ||
| Q1 24 | $195.1M | — |
| Q4 25 | $444.4M | — | ||
| Q3 25 | $480.6M | — | ||
| Q2 25 | $489.0M | — | ||
| Q1 25 | $493.9M | $406.9M | ||
| Q4 24 | $493.9M | $271.6M | ||
| Q3 24 | $502.7M | — | ||
| Q2 24 | $463.9M | — | ||
| Q1 24 | $461.1M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | $131.8M |
| Free Cash FlowOCF − Capex | $-14.7M | $131.7M |
| FCF MarginFCF / Revenue | -6.0% | 83.0% |
| Capex IntensityCapex / Revenue | 0.1% | 0.1% |
| Cash ConversionOCF / Net Profit | -0.21× | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | $-17.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.4M | — | ||
| Q3 25 | $5.5M | — | ||
| Q2 25 | $642.0K | — | ||
| Q1 25 | $-5.6M | $131.8M | ||
| Q4 24 | $-9.0M | $-23.2M | ||
| Q3 24 | $9.0M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $-27.3M | — |
| Q4 25 | $-14.7M | — | ||
| Q3 25 | $4.7M | — | ||
| Q2 25 | $-575.0K | — | ||
| Q1 25 | $-6.7M | $131.7M | ||
| Q4 24 | $-10.2M | $-23.2M | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $432.0K | — | ||
| Q1 24 | $-29.4M | — |
| Q4 25 | -6.0% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | -0.2% | — | ||
| Q1 25 | -2.6% | 83.0% | ||
| Q4 24 | -4.2% | -102.7% | ||
| Q3 24 | 2.9% | — | ||
| Q2 24 | 0.2% | — | ||
| Q1 24 | -14.7% | — |
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 0.4% | — | ||
| Q1 25 | 0.4% | 0.1% | ||
| Q4 24 | 0.5% | 0.2% | ||
| Q3 24 | 0.5% | — | ||
| Q2 24 | 0.3% | — | ||
| Q1 24 | 1.0% | — |
| Q4 25 | -0.21× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DOUG
| Commissions And Other Brokerage Income | $240.3M | 98% |
| Property Management Income | $2.8M | 1% |
| Property Management | $2.2M | 1% |
STOK
Segment breakdown not available.
